TRI.TO -0.02C -1.89GFL.TO 2.01BRK.B -4.78PLUS -0.79TGTX 1.01LLY -33.23SU.TO 2.79
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

30.03
-0.39 (1.28%)
as of Oct 23, 2026, 8:00:00 pm Market Closed.
585 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
TRADE

Pfizer Inc(PFE)

Dec 09, 2008
Manufactures of the drug lipidore (the most popular cholesterol drug) Their patent is running out in 2011 - 2012 and they are considering walking away and getting into cancer drugs.
Photo of Alan Kral , CFA, CICAlan Kral , CFA, CICUnlock Rating
$16.47

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
Track your Stocks in your Watch List
DON'T BUY

Pfizer Inc(PFE)

Dec 01, 2008
Health care space, specifically drugs and bio pharmaceuticals is interesting but this is not one that he would Buy. Continue to have issues with drugs coming off of patents and relatively low revenue growth. Would prefer something like Gilead Sciences (GILD-Q) or a generic like Teva (TEVA-Q). This is an area where you should have some exposure.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$15.28

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Nov 14, 2008
High dividend yield. Cheap because people think there is not much in the pipeline. Lipitor will be going off patent so earnings will drop. Almost like a short-term bond in that you get cash flow from existing drugs that are pretty dependable but not much growth. Sold his holdings about 2 years ago because of lack of growth. Relatively safe but not a lot of upside.
Photo of Charles BobrinskoyCharles Bobrinskoy
No
Unlock Rating
$16.28

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 12, 2008
Have a lot of cash and produce a lot of cash flow. Very high dividend. They cannot seem to get any catalyst for growth. A lot of competition from generic drug companies.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$15.83

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Oct 22, 2008
Losing Lipitor in a couple of years but thinks this is priced into the stock. They are doing cost cutting. Pipeline is a little weak. From a historic PE level and dividend it is a very attractive value. However, if the US is to regulate more and put price fixing on drugs, that would definitely be a negative.
Photo of David AbellaDavid Abella
Owned
Unlock Rating
$16.74

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 07, 2008
Interesting sock. Almost like a bond. Price assumes there will be no significant new drugs so revenue is based on existing drugs until they come off patent. No phase 2 drugs have hit over the last 2 years.
Photo of Charles BobrinskoyCharles BobrinskoyUnlock Rating
$17.65

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 16, 2008
Drugs are coming off patent and are they going to be able to replenish the pipeline? Does management have the ability to keep the cash flow chugging along? The market is telling you No. 7% yield but that there is very little else.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$17.81

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 11, 2008
Value manager’s dream but never has done anything. He has a model price of $30.26. 66% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$18.39

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 03, 2008
Trendline and 200-day moving average have been moving down. It has not made a base.
Photo of Ron MeiselsRon MeiselsUnlock Rating
$19.20

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 27, 2008
Owned it about a year ago with a theory that their drugs were worth what the stock price was going at hand you would make money on all the new drugs they developed. The problem is, they haven't developed any new drugs in almost 3 years. Would prefer Merck (MRK-N).
Photo of Charles BobrinskoyCharles Bobrinskoy
No
Unlock Rating
$19.08

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 22, 2008
Worth considering at this price. Very cheap. Double-digit free cash flow yield and very attractive dividend yield. Lipitor will be coming off patent and pipeline of new drugs is relatively thin. Will be lucky to have 0% growth over the next 5 years but over the very long term they will get the pipeline filled.
Photo of Paul LarsonPaul Larson
Owned
Unlock Rating
$19.75

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 21, 2008
Pharmaceutical group is behaving better. This one is less attractive and is facing drugs coming off patent. Prefers others.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$19.37

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Aug 06, 2008
Earnings where fantastic. Yield of 6.6%.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$19.43

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Jul 16, 2008
At an interesting Buy point but not sure he would buy it currently. On his Watch list.
Photo of Peter BriegerPeter Brieger
No
Unlock Rating
$18.26

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jul 11, 2008
(Market Call Minute.) Broken stock and he can't see what is going to turn it around.
Photo of David BurrowsDavid BurrowsUnlock Rating
$17.81

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
Showing 511 to 525 of 894 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

AMZN -2.38$248
META -6.23$642.62
VRT -1.27$194.32
WFC -0.62$82.39
ZS 17.39$255.15

Today's Top Picks

TRI.TO -0.02$172.41
C -1.89$120.62
GFL.TO 2.01$63.75
BRK.B -4.78$542.19
PLUS -0.79$95.36

Popular Articles

Latest Sell Signals

DOV 0$
BA 0.8$188.35
AC.TO -1.03$21.11
BB.TO 0.44$12.46
TSM 6.16$418.51

Most Recent Experts

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Jason Snipe, CIO, Odyssey Capital Advisors

Jason Snipe, CIO, Odyssey Capital Advisors

Odyssey Capital Advisors

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Tim Regan

Tim Regan

Kingwest & Company

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like